- In May 2024, the Serum Institute of India (SII) revealed plans to acquire a 20% stake in IntegriMedical as part of its strategic initiative to enhance its capabilities in needle-free injection system (NFIS) technology. This investment aims to bolster SII's position in the growing market for innovative drug delivery solutions, aligning with its commitment to advancing healthcare technologies. By collaborating with IntegriMedical, SII seeks to accelerate the development and implementation of cutting-edge needle-free systems to improve patient outcomes
- In April 2023, PharmaJet partner Gennova Biopharmaceuticals submitted data for its needle-free mRNA-based booster shot targeting the Omicron variant of COVID-19 to the Drug Controller General of India (DCGI) for Emergency Use Authorization (EUA). This submission marks a significant step forward in expanding vaccination options by utilizing innovative needle-free technology. If approved, this booster shot could enhance accessibility and reduce discomfort for patients, contributing to ongoing efforts to combat the pandemic
- In March 2023, NuGen Medical Devices released a report highlighting the performance of its needle-free injection device, InsuJet™, which demonstrated over 40% faster insulin uptake and a significantly quicker onset of action in diabetic patients compared to traditional needle injections. These findings were based on multiple clinical studies conducted in the Netherlands, showcasing the potential benefits of InsuJet™ in enhancing diabetes management. This innovative technology offers a promising alternative for insulin delivery, aiming to improve patient outcomes and comfort
- In October 2022, NuGen Medical Devices Inc. announced the launch of its InsuJet devices in Canada, designed to deliver 5,000 insulin injections. This innovative device significantly reduces long-term injection costs while minimizing biomedical waste and the risk of needle-stick injuries. Additionally, InsuJet offers a more comfortable and anxiety-free medication experience for patients, enhancing overall treatment adherence and quality of life
Frequently Asked Questions
The market is segmented based on Global Needle-Free Drug Delivery Market Segmentation, By Product (Prefilled Needle-Free Injection Systems and Fillable Needle-Free Injection Systems), Technology (Inhaler, Novel Needle-Free, Jet Injector and Transdermal Patch), Application (Insulin Delivery, Vaccination, Pediatric Injections, and Pain Management), Injection Method (Powder injections, Liquid injections, and Depot or Projectile Injection), Source of Power (Spring Load Jet Injector Systems, Gas Powdered Jet Injector, and Battery Powdered Jet Injector System) – Industry Trends and Forecast to 2031
.
The Global Needle Free Drug Delivery Market size was valued at USD 13.09 USD Billion in 2023.
The Global Needle Free Drug Delivery Market is projected to grow at a CAGR of 9.95% during the forecast period of 2024 to 2031.
The major players operating in the market include Antares Pharmed , Tianjin Xuying Technology Development Co. , Verdict Media Limited, 3M PharmaJet, Zogenix, Inovio Pharmaceuticals , Valeritas , Akra Dermo-Jet, D'Antonio Consultants International , Endo Pharmaceuticals , BD, CROSSJECT MIT Canada, MedImmune, Mystic Pharmaceuticals, Needle Free Injection System, Inolife Sciences, Ferring B.V., OptiNose US , Pfizer -.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
